These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1230 related articles for article (PubMed ID: 33949150)

  • 1. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.
    Fan T; Zhu M; Wang L; Liu Y; Tian H; Zheng Y; Tan F; Sun N; Li C; He J
    Aging (Albany NY); 2020 Dec; 13(2):2397-2417. PubMed ID: 33318300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13.
    Wang J; Shi W; Miao Y; Gan J; Guan Q; Ran J
    Bioengineered; 2021 Dec; 12(1):6286-6304. PubMed ID: 34494914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences.
    Fan T; Li C; He J
    Biol Sex Differ; 2021 Dec; 12(1):64. PubMed ID: 34863300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
    Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
    Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and Evaluation of a 6-Gene Survival Risk Assessment Model Related to Lung Adenocarcinoma Microenvironment.
    Wang Z; Xu H; Zhu L; He T; Lv W; Wu Z
    Biomed Res Int; 2020; 2020():6472153. PubMed ID: 32337264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 13. CCR2 and PTPRC are regulators of tumor microenvironment and potential prognostic biomarkers of lung adenocarcinoma.
    Wei J; Fang D; Zhou W
    Ann Transl Med; 2021 Sep; 9(18):1419. PubMed ID: 34733971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma.
    Tao Y; Li Y; Liang B
    Future Oncol; 2020 Aug; 16(24):1825-1837. PubMed ID: 32501723
    [No Abstract]   [Full Text] [Related]  

  • 15. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 16. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO.
    Wen S; Peng W; Chen Y; Du X; Xia J; Shen B; Zhou G
    BMC Cancer; 2022 Feb; 22(1):193. PubMed ID: 35184748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1 Is a Potential Prognostic Factor Associated with the Tumor Microenvironment in Lung Adenocarcinoma.
    Wang L; Gao M; Sun D; Wu H; Lv S; Li Y; Li L
    Biomed Res Int; 2022; 2022():7848771. PubMed ID: 35941968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of key genes in the tumor microenvironment of lung adenocarcinoma.
    Long W; Li Q; Zhang J; Xie H
    Med Oncol; 2021 Jun; 38(7):83. PubMed ID: 34117948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
    Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
    Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.